San­ther­a's clin­i­cal da­ta are in, but NDA de­layed 4-6 months by third par­ty man­u­fac­tur­er

San­thera Phar­ma­ceu­ti­cals fin­ished sub­mit­ting the clin­i­cal por­tion of its rolling NDA yes­ter­day, but the Swiss biotech’s reg­u­la­to­ry am­bi­tions are now pushed back four to six …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER